Hashimoto's Thyroiditis
Autoimmune thyroid disease causing glandular destruction and hypothyroidism. MSC therapy modulates thyroid autoimmunity and reduces inflammatory damage.
Hashimoto's thyroiditis is the most common autoimmune disease and the leading cause of hypothyroidism in the developed world, affecting approximately 14 million Americans. The immune system produces antibodies against thyroid peroxidase (TPO) and thyroglobulin (TG), and cytotoxic T cells infiltrate and progressively destroy thyroid glandular tissue.
Patients suffer from hypothyroidism-related fatigue, weight gain, cold intolerance, hair thinning, brain fog, and depression — as well as the systemic burden of chronic autoimmunity, including arthralgia, fibromyalgia-like pain, and elevated cardiovascular risk. Standard care is levothyroxine replacement, which addresses hormone deficiency but not the underlying autoimmune process.
MSC therapy represents a rational immunological intervention for Hashimoto's — targeting the autoimmune mechanism rather than simply replacing what the immune system has destroyed.
MSCs suppress the Th1-dominant immune response characteristic of Hashimoto's through direct T-cell inhibition, Treg expansion, and secretion of IL-10 and TGF-β. Reduction in TPO antibody and TG antibody titers has been observed in patients receiving MSC therapy in case series and small trials, consistent with immune tolerance induction.
In addition to immune modulation, MSCs secrete hepatocyte growth factor and other trophic factors that support thyrocyte survival and may partially preserve remaining glandular function. Some patients in published reports experienced improvements in thyroid ultrasound appearance — reduced echogenicity, inflammation, and nodularity — alongside antibody reduction.
True Regen coordinates a full thyroid evaluation — including TSH, free T4/T3, TPO antibodies, TG antibodies, and thyroid ultrasound — before treatment. Antibody levels and thyroid function are tracked at 3, 6, and 12 months post-treatment to assess immunological response.
- Reduction in TPO and TG antibody titers
- Improved thyroid ultrasound appearance
- Reduced fatigue and cognitive fog
- Potential reduction in levothyroxine requirements
- Lower systemic inflammatory burden
Individual results vary. All patients undergo full medical evaluation prior to treatment.
ISO/cGMP-Certified Lab
Every infusion is manufactured under pharmaceutical-grade controls. You receive a batch-specific Certificate of Analysis before treatment.
High-Dose MSC Protocol
Wharton's jelly umbilical-cord MSCs — younger, more potent, and more consistent than cells from the patient's own body.
Dedicated Coordinator
One person manages every detail of your journey — from your first inquiry through your 12-month follow-up.
Ready to take the next step?
One conversation could change everything.
Your dedicated coordinator will review your case and walk you through the entire process — with zero pressure, zero cost, and zero commitment.